Comparative Pharmacology
Head-to-head clinical analysis: BRISTAGEN versus NEOMYCIN SULFATE DEXAMETHASONE SODIUM PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISTAGEN versus NEOMYCIN SULFATE DEXAMETHASONE SODIUM PHOSPHATE.
BRISTAGEN vs NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bristagen (amikacin) is an aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. Dexamethasone is a corticosteroid that induces phospholipase A2 inhibitory proteins, thereby suppressing prostaglandin and leukotriene synthesis, reducing inflammation.
1-2 mg/kg IM or IV every 8-12 hours; typical adult dose is 1 mg/kg every 8 hours.
Ophthalmic: 1-2 drops of the solution or small amount of the ointment (approximately 1/2 inch into the conjunctival sac) every 3-4 hours, or more frequently if needed. Otic: 4 drops into the affected ear 3-4 times daily.
None Documented
None Documented
2.5 hours (prolonged to 20-40 hours in renal impairment).
Neomycin: terminal half-life ~2-3 hours after oral absorption (negligible systemic absorption); in renal impairment, half-life can extend to 12-24 hours. Dexamethasone: terminal half-life ~36-54 hours (mean ~48 hours) in adults.
Renal (90% unchanged via glomerular filtration); biliary/fecal excretion <10%.
Neomycin is primarily excreted unchanged in feces (~97%) after oral administration, with about 1% absorbed and renally excreted. Dexamethasone is metabolized in liver and excreted renally (~65% as metabolites, 2-5% unchanged) and in feces (~20%).
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic